until disease progression, unacceptable toxicity, or completion of 6 cycles. The primary endpoint is progression-free survival, as assessed by the Independent Radiology Review Committee, in patients with ≥ 5% PD-L1 tumor expression. EFTA00822174 Daniel Lundquist Healthcare Specialist Sales Global Equities The power of global co